Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease
Haley, Connie A. , Ashkin, David , Peloquin, Charles A. , Cegielski, J. Peter , Andrino, Barbara B, Burgos, Marcos, Caloia, Lori A, Chen, Lisa , Colón‐Semidey, Angel, DeSilva, Malini B. , Dhanireddy, Shireesha , Dorman, Susan E. , Dworkin, Felicia , Hammond-Epstein, Heidi, Easton, Alice V. , Gaensbauer, James , Ghassemieh, Bijan J., Gómez, María Elena, Horné, David , Jasuja, Supriya , Jones, Betsy A., Kaplan, Leonard J., Khan, Asharaf Edward, Kracen, Elizabeth, Labuda, Sarah M. , Landers, Karen M., Lardizabal, Alfred , Lasley, Maria T, Letzer, David, Lopes, Vinicius K, Lubelchek, Ronald , Macias, C. Patricia, Mihalyov, Aimee, Misch, Elizabeth Ann , Murray, Jason A., Nilsen, Diana , Ninneman, M.J., Ogawa, Lynne, Oladele, Alawode, Overman, Melissa C, Ritger, Kathleen A., Rowlinson, Marie‐Claire , Sabuwala, Nadya, Schiller, Thomas M, Schwartz, Lawrence E., Spitters, Christopher, Thomson, Douglas B, Tresgallo, Rene Rico, Valois, Patrick , Goswami, Neela D. , Group, for the BPaL Implementation, Agraz-Lara, Rocio, Ahmed, Amina , Alvarez, Ana , Armitage, Lisa, Belknap, Robert , Bravo, Mary, Brode, Sarah K. , Burden, Elizabeth, Burzynski, Joseph , Caplan‐Shaw, Caralee , Castro, Ken, Chorba, Terry, Cook, Victoria , Cruz, Andrea T. , Dasgupta, Shom, Dhingra, Sonia, Elmore, Ellen, Erwin, Frank, Escuyer, Vincent, Fiske, Christina T. , Gadkowski, Beth, Henestroza, Germán, Higashi, Julie, Keh, Chris , Khalil, Amanda , Kigonya, Lilian, Lauzardo, Michael , Morris, Sapna Bamrah , Nabity, Scott A. , Oxtoby, Margaret J., Patrawalla, Amee , Raftery, Ann, Reed, Caitlin , Rock, Brian, Russo, Kelly, Sahini, Harleen, Saleeb, Paul , Santos, Roberto P. , Seaworth, Barbara , Shaw-Kaikai, Joanna, Starke, J R, Stout, Jason E. , Stubblefield, Wesley, Temesgen, Zelalem , Thomas, Keziah, Urbine, Daniel , Warkentin, Jon, Webb, Risa M. , Wortham, Johnathan, Yu, and Salinia, Altman, C, Hafiz, Irfan, Prabhakar, Deepa, Bowler, William, Gaensbauer, James T , Peloquin, Charles A , Schechter, Marcos C , Narita, Masahiro , Ray, Susan M , Group, for the BPaL Implementation, Alvarez, Ana, Armitage, Lisa, Barry, Pennan M. , Bernardo, John , Connors, William J. A. , Daley, Charles L. , Dobbs, Thomas E. , Escuyer, Vincent , Katrak, Shereen S. , Munsiff, Sonal S. , Phillips, Allison, Stubblefield, Wes, Thomas, Keziah, Tornheim, Jeffrey A. , Upton, Caryn M. , Wang, Shuhua , Wilson, John , Altman, Claudia

Mayo Clinic

Clinical Infectious Diseases | May 30, 2023 | Volume: 77 | Issue: 7 | Pages: 1053-1062

10.1093/cid/ciad312 | PMID 37249079 Get It

Abstract Background Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only one-third of persons start treatment, and outcomes are often inadequate. Several trials demonstrate 90% efficacy using an all-oral, 6-month regimen of bedaquiline, pretomanid, and linezolid (BPaL), but significant toxicity occurred using 1200-mg linezolid. After US Food and Drug Administration approval in 2019, some US clinicians rapidly implemented BPaL using an initial 600-mg linezolid dose adjusted by serum drug concentrations and clinical monitoring. Methods Data from US patients treated with BPaL between 14 October 2019 and 30 April 2022 were compiled and analyzed by the BPaL Implementation Group (BIG), including baseline examination and laboratory, electrocardiographic, and clinical monitoring throughout treatment and follow-up. Linezolid dosing and clinical management was provider driven, and most patients had linezolid adjusted by therapeutic drug monitoring. Results Of 70 patients starting BPaL, 2 changed to rifampin-based therapy, 68 (97.1%) completed BPaL, and 2 of the 68 (2.9%) experienced relapse after completion. Using an initial 600-mg linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory monitoring for adverse effects, supportive care, and expert consultation throughout BPaL treatment, 3 patients (4.4%) with hematologic toxicity and 4 (5.9%) with neurotoxicity required a change in linezolid dose or frequency. The median BPaL duration was 6 months. Conclusions BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelines for drug-resistant tuberculosis. Use of individualized linezolid dosing and monitoring likely enhanced safety and treatment completion. The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the United States is feasible.
Uterine fibroid volume is not associated with blood pressure
Pruter, Wyatt W. , El-Borgi, Cecile, Harvey, Ronée E. , Stewart, Elizabeth A. , Baker, Sarah E.

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5733950 Get It

Background: Females with uterine fibroids (UF), benign tumors of the myometrium, have a higher risk of hypertension than females without UF. The relationship between UF and hypertension is not fully understood. Case studies have reported hypertension in patients with large UF that compress the ureters, resulting in hydronephrosis. However, this pathophysiology is not present in all females with UF and hypertension. It is unknown if UF volume is correlated with blood pressure in the absence of renal compromise. Therefore, the goal of this study was to determine the potential associations between blood pressure and 1) volume of the largest UF and 2) volume of the uterus (a surrogate for total UF volume) in females with UF. Methods: We utilized the Mayo Clinic Data Explorer to identify patients, who had pelvic ultrasound or magnetic resonance imaging (MRI) studies performed at Mayo Clinic-Rochester in 2021 that reported the presence of UF, and who were ages 18-65 years old. From this system, we collected brachial blood pressure data (systolic, diastolic, and mean), assessed in the outpatient setting within 14 days of imaging. For each patient, dimensions of the largest UF and the uterus were abstracted from radiology reports. The largest UF was assessed, as it reliably had all three dimensions reported. Volume of the uterus was used as a surrogate for total UF volume to consider the possibility of multiple UF that were not detailed in the radiology report. Volumes of the largest UF and uterus were each calculated as for ellipsoid structures, (length✕depth✕width)✕0.523 in cm3. The Pearson correlation coefficient (r) was calculated to assess the linear relationship between blood pressure and largest UF volume, and blood pressure and uterine volume. A p-value <0.05 denoted statistical significance. Results: One hundred thirteen females (48±9 years old) were included in the analysis, 88 with ultrasound and 25 with MRI reports. Average blood pressures were as follows, systolic: 121±16 mmHg (range: 92-185 mmHg), diastolic: 76±9 mmHg (52-101 mmHg), and mean: 91±11 mmHg (67-129 mmHg). Twenty-nine females (25.7%) had a diagnosis of hypertension. Hydronephrosis was not reported in any of the imaging reports. A mean of 2±2 UF were present per uterus (range: 1-15). Average volume of the largest UF was 75.0±115.9 cm3. Largest UF volume was not associated with systolic (r=0.023, p=0.812), diastolic (r=-0.040, p=0.677), or mean (r=-0.014, p=0.881) blood pressures. Average volume of the uterus was 219.6±215.6 cm3. Volume of the uterus was not associated with systolic (r=0.040, p=0.688), diastolic (r=0.102, p=0.305), or mean (r=0.071, p=0.475) blood pressures. Conclusion: In females with UF, blood pressure is not associated with the largest UF or uterine volumes. These data suggest that in the absence of hydronephrosis, the association between UF and blood pressure is not related to UF size. It is unknown if these findings differ based on factors, such as race. AHA 898649, NIH K01 HL1148144 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Central alpha-2 adrenergic mechanisms affect human sympathetic neuronal discharge strategies
Limberg, Jacqueline K. , Iannarelli, Nathaniel , Nicholson, Wayne T. , Joyner, Michael J. , Shoemaker, J. Kevin , Shoemaker, J Kevin , Joyner, Michael J , Klassen, Stephen A. , Harvey, Ronée E. , Wiggins, Chad C. , Senefeld, Jonathon W. , Curry, Timothy B. , Baker, Sarah E.

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5733156 Get It

The central neural mechanisms affecting sympathetic neuronal discharge strategies supporting homeostatic adjustments in human muscle sympathetic nerve activity (MSNA) remain unclear. This study investigated the hypothesis that central alpha-2 adrenergic mechanisms affect sympathetic action potential (AP) discharge, recruitment, and latency patterns within human MSNA (peroneal nerve microneurography and continuous wavelet transform). An alpha-2 adrenergic agonist (dexmedetomidine) was infused in eight healthy male and female participants (5 females; 28 ± 7years). Data were recorded during a 5-minute resting control condition, a 10-minute intravenous dexmedetomidine loading dose (0.225 μg/kg), and a dexmedetomidine maintenance dose (~0.1 μg/kg/hr). Data are reported as mean (SD) for the 5-minute control condition and 2-minutes of the dexmedetomidine infusion when MSNA bursting activity was demonstrably reduced. Two-tailed paired t-tests were performed. Dexmedetomidine reduced mean pressure (92 ± 7 to 80 ± 8 mmHg; P < 0.01) but did not affect heart rate (61 ± 13 to 60 ± 14 bpm; P = 0.75). Dexmedetomidine reduced integrated MSNA burst frequency (14 ± 6 to 4 ± 3 bursts/min; P < 0.01), sympathetic AP frequency (75 ± 46 to 16 ± 14 AP/min; P < 0.01), APs per burst (5 ± 1 to 4 ± 1 AP/burst; P = 0.01), AP clusters per burst (3.5 ± 0.7 to 3.0 ± 0.7 clusters/burst; P = 0.03), and de-recruited the largest AP clusters (12 ± 3 to 7 ± 2 AP clusters; P < 0.01). Despite de-recruiting large AP clusters with short conduction times, dexmedetomidine elicited shorter sympathetic AP conduction times (1.18 ± 0.12 to 1.14 ± 0.13 s; P = 0.03). Six participants performed a Valsalva Maneuver (20 s, 40 mmHg mouth pressure) during the control condition and during the dexmedetomidine maintenance dose. Data are reported as mean (SD) change (Δ) from the 2-minute period preceding the Valsalva Maneuver to the Valsalva Maneuver for each condition. During the control condition, Valsalva Maneuver increased AP frequency (Δ 311 ± 317 AP/min; P = 0.048), recruited larger previously silent AP clusters (Δ 2 ± 1 AP clusters; P < 0.01), and elicited shorter AP conduction times (Δ ‑0.09 ± 0.07 s; P = 0.02). Compared to the control condition, Valsalva Maneuver performed during the dexmedetomidine maintenance dose condition elicited lesser increases in AP frequency (Δ 116 ± 189 AP/min; P vs. control = 0.02) and lesser recruitment of larger previously silent AP clusters (Δ 0 ± 1 AP clusters; P vs. control = 0.02). Dexmedetomidine did not affect the latency reduction elicited by Valsalva Maneuver (Δ ‑0.07 ± 0.14 s; P vs. control = 0.61). These data suggest that human central alpha-2 adrenergic mechanisms affect: i) sympathetic postganglionic neuronal discharge and recruitment patterns, and ii) synaptic delays within the sympathetic neurocircuitry influencing AP latency. This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the National Institutes of Health (NIH). This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Nitric oxide contribution to endothelium-mediated vasodilation is attenuated in postmenopausal compared to premenopausal females
Pruter, Wyatt W. , Limberg, Jacqueline K. , Joyner, Michael J. , Joyner, Michael J , Barnes, Jill N. , Ranadive, Sushant M. , Baker, Sarah E. , Curry, Timothy B. , Harvey, Ronée E.

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5731130 Get It

Background: Hypertension prevalence increases in females following menopause. Poor endothelial microvascular function increases risk of hypertension. Endothelial-mediated vasodilation is dependent on nitric oxide (NO). Estrogen enhances NO production; therefore, reduced estrogen levels in postmenopausal females may result in a reduced contribution of NO to endothelial-mediated vasodilation, although studies are limited. Herein, we aimed to investigate the contribution of NO to endothelial-mediated vasodilation in premenopausal and postmenopausal females. We hypothesized that postmenopausal females would have attenuated endothelium-mediated vasodilation and reduced contribution of NO compared to premenopausal females. Methods: Ten premenopausal (27±3 yrs) and eleven postmenopausal (59±4 yrs) normotensive females were studied. Resting brachial blood pressures were measured using a standard arm cuff. Brachial arterial catheters were placed for continuous blood pressure measurement and pharmacologic infusions. Forearm blood flow (FBF) was measured using venous occlusion plethysmography at baseline (saline) and during infusion of an endothelium-dependent vasodilator (acetylcholine; 1.0, 2.0, 4.0, and 8.0 μg/100mL tissue/min) with and without a NO synthase inhibitor (L-NG-monomethylarginine [L-NMMA]; 1.0 mg/min) co-infusion. Forearm vascular conductance (FVC) was calculated as FBF/mean arterial pressure✕100. Data were analyzed using a two-way repeated-measures ANOVA. Results: Resting systolic blood pressure (SBP) but not diastolic blood pressure (DBP) was greater in postmenopausal compared to premenopausal females (SBP: 121±15 vs. 103±9 mmHg, respectively; P<0.01; DBP: 72±11 vs. 65±5 mmHg, respectively; P=0.07). FBF responses to acetylcholine did not differ between premenopausal and postmenopausal females (Group Main Effect: P=0.11). When correcting for blood pressure, premenopausal females exhibited greater FVC responses to acetylcholine compared to postmenopausal females (Group Main Effect: P=0.04). In premenopausal females, FBF and FVC responses to acetylcholine were reduced with co-infusion of L-NMMA compared to acetylcholine infusion only (L-NMMA Main Effect: P=0.02 and P=0.01, respectively). In postmenopausal females, the FBF and FVC responses to acetylcholine were unaffected by L-NMMA (L-NMMA Main Effect: P=0.79 and P=0.76, respectively). Conclusion: Compared to premenopausal females, postmenopausal females have impaired endothelial microvascular function. Attenuated NO contribution during endothelium-mediated vasodilation in postmenopausal women may partially contribute to the increased hypertension risk in this population. AHA 14PRE18040000, AHA 898649, NIH HL083947, NIH HL148144, NCATS UL1 TR000135 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
0326 Symptom trajectories in adults with stable heart failure and insomnia: Evidence from a randomized controlled trial of CBT-I
Wang, Zequan , Tocchi, Christine , Linsky, Sarah , O’Connell, Meghan , Conley, Samantha , Jeon, Sangchoon , Redeker, Nancy S.

Mayo Clinic

SLEEP | May 29, 2023 | Volume: 46 | Issue: Supplement_1 | Pages: A145-A145

10.1093/sleep/zsad077.0326 Get It

Abstract Introduction Cognitive behavioral therapy for insomnia (CBT-I) improves individual symptoms of fatigue and daytime sleepiness; however, little is known how CBT-I improves multiple co-occurring daytime symptoms. The purposes of this study are to (1) identify daytime symptom trajectories in adults with insomnia and stable chronic heart failure (HF) over one year, and (2) determine how symptom trajectories vary based on participation in CBT-I or HF self-management education (attention control condition). Methods We conducted a retrospective analysis of data from a randomized controlled trial that looked the sustained effects of CBT-I compared to HF self-management over one year (NCT02660385). We measured daytime symptoms (fatigue, depression, anxiety, dyspnea, pain, and daytime sleepiness) at baseline (pre-treatment) and 3, 6 and 12 months. Symptom cluster trajectory were identified using group-based trajectory modeling, and the association with CBT-I was examined using logistic regressions. Results We randomized 175 participants (M age=63.0 (12.9) years, 57% men). We found four daytime symptom cluster trajectories, (A) low improving symptoms (N = 67, 38.3%); (B) low psychological symptoms and high improving physical symptoms (N = 40, 22.8%); (C), high improving symptoms (N = 42, 24.0%); and (D) high not improving symptoms (N = 26, 14.9%). There was no statistically significant difference between CBT-I and HF self-management across 4 symptom trajectories (p = .2509). However, people who received CBT-I vs. HF self-management education had higher odds of belonging to trajectory A compared to B/C/D after controlling for baseline fatigue (OR = 3.27 95% Confidence Intervals [1.39, 7.68]). Conclusion Most participants experienced improved daytime symptom profiles over 12 months after both interventions. Participants in the CBT-I group experienced symptom improvement even when they started with low symptoms. Support (if any) National Institute of Nursing Research [R01NR016191 and P20NR014126].
Inclusion, Diversity, Access, and Equity in Infectious Diseases Fellowship Training: Tools for Program Directors
Luther, Vera , Barsoumian, Alice E , Konold, Victoria , Balba, Gayle , Benson, Constance A. , Blackburn, Brian G. , Cariello, Paloma F, Perloff, Sarah , Acharya, Kartikey, Bhanot, Nitin , Blyth, Dana M , Casańas, Beata, Chow, Brian , Cutrell, James B , Doshi, Saumil, Finkel, Diana , Graber, Christopher J. , Hazra, Aniruddha , James, Scott H. , Kodiyanplakkal, Rosy Priya , Lee, Mi-Kyung , Marcos, Luis A. , Lora, Alfredo J Mena , Moore, Christopher C. , Nnedu, Obinna, Osorio, Georgina, Reece, Rebecca , Salas, Natalie Mariam , Sanasi-Bhola, Kamla, Schultz, Sara , Serpa, José A., Shnekendorf, Rachel, Wooten, Darcy , Zuckerman, Richard A. , Melia, Michael T. , Chirch, Lisa M , Luther, Vera P , Razonable, Raymund, Azar, Marwan M , Graber, Christopher J , Lee, Mikyung , Vijayan, Tara , Razonable, Raymund R. , Azar, Marwan M. , Butt, Saira , Cleveland, Kerry O. , Hochberg, Natasha S. , Kaltsas, Anna , Paras, Molly L , Weisenberg, Scott A.

Mayo Clinic

Open Forum Infectious Diseases | May 27, 2023 | Volume: 10 | Issue: 6 | Pages: No page available

10.1093/ofid/ofad289 | PMID 37397270 Get It

Abstract The Infectious Diseases Society of America (IDSA) has set clear priorities in recent years to promote inclusion, diversity, access, and equity (IDA&E) in infectious disease (ID) clinical practice, medical education, and research. The IDSA IDA&E Task Force was launched in 2018 to ensure implementation of these principles. The IDSA Training Program Directors Committee met in 2021 and discussed IDA&E best practices as they pertain to the education of ID fellows. Committee members sought to develop specific goals and strategies related to recruitment, clinical training, didactics, and faculty development. This article represents a presentation of ideas brought forth at the meeting in those spheres and is meant to serve as a reference document for ID training program directors seeking guidance in this area.
Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831
Hodgson, David C. , Lee, Inki , Pei, Qinglin , Wu, Yue , McCarten, Kathleen M. , Hoppe, Bradford S. , Roberts, Kenneth B. , Milgrom, Sarah A. , Kessel, Sandy, Cole, Peter D. , Kelly, Kara M. , Hodgson, David C , Milgrom, Sarah , Cole, Peter D , Hoppe, Bradford S , Hodgson, David , Cho, Steve Y.

Mayo Clinic

Pediatric Blood & Cancer | May 27, 2023 | Volume: 70 | Issue: 8 | Pages: No page available

10.1002/pbc.30452 | PMID 37243975 Get It

AbstractPurpose/objectiveWe compared the prognostic value of chest radiograph (CXR)‐ and computed tomography (CT)‐derived definition of large mediastinal adenopathy (LMA) in pediatric Hodgkin lymphoma (HL).Materials/methodsTotal 143 patients treated for stage IIIB/IVB HL on COG AHOD0831 were included in this study. Six definitions of LMA were investigated: (i) mediastinal mass ratio on CXR (MRCXR) > 1/3; (ii) mediastinal mass ratio on CT (MRCT) > 1/3; (iii) mediastinal mass volume on CT (MVCT) > 200 mL; (iv) normalized mediastinal mass volume (MVCT/thoracic diameter [TD]) > 1 mL/mm; (v) mediastinal mass diameter on CT (MDCT) > 10 cm; and (vi) normalized mediastinal mass diameter (MDCT/TD) > 1/3.ResultsMedian age at diagnosis was 15.8 years (range: 5.2–21.3 years). In patients with a slow early response (SER) to chemotherapy, MVCT > 200 mL, MDCT > 10 cm, and MDCT/TD > 1/3 were associated with worse relapse‐free survival (RFS) on MVA, while MRCXR > 1/3, MRCT > 1/3, and MVCT/TD > 1 mL/mm trended toward worse RFS; MDCT/TD was the most strongly prognostic for inferior RFS, with a hazard ratio of 6.41 for MDCT/TD > 1/3 versus ≤1/3 on MVA (p = .02).ConclusionLMA according to MVCT > 200 mL, MDCT > 10 cm, and MDCT/TD > 1/3 is associated with poor prognosis in advanced‐stage HL patients with SER. The normalized mediastinal diameter, MDCT/TD > 1/3 appears to be the strongest predictor of inferior RFS.
Views of parents of children with Down syndrome on Alzheimer’s disease vaccination
Batbold, Sarah , Cummings, Gabrielle , Riggan, Kirsten A. , Michie, Marsha , Allyse, Megan , Allyse, Megan A , Riggan, Kirsten A

Mayo Clinic

Journal of Intellectual Disabilities | May 25, 2023 | Volume: 28 | Issue: 3 | Pages: 759-772

10.1177/17446295231177787 | PMID 37226465 Get It

Individuals with Down syndrome (DS) experience increased risk of Alzheimer’s disease (AD). Recent studies suggest that a vaccine against AD may be forthcoming. Parental buy-in is critical to the success of any intervention in this population, as adults with DS often rely on familial support. This study aims to characterize parents’ perceptions of a hypothetical vaccine to prevent AD in individuals with DS. A mixed-methods, anonymous survey was distributed via social media. Participants were asked about their experiences with DS and reactions to proposed interventions. Open-ended responses were thematically analyzed using NVivo 12. Of 1,093 surveys initiated, 532 were completed. Of the parents sampled (N = 532), a small majority (54.3%), supported the proposed AD vaccine. All expressed the need for extensive pre-enrollment education and minimal risk. For many, limited research and long-term sequelae were concerns.
Evaluation of advanced imaging biomarkers at kidney failure in patients with ADPKD: a pilot study
Wigerinck, Stijn , Gregory, Adriana , Iliuta, Ioan-Andrei, Hanna, Christian , Chedid, Maroun , Kaidbay, Hasan-Daniel N., Senum, Sarah R. , Shukoor, Shebaz, Harris, Peter C. , Kline, Timothy L. , Gregory, Adriana V, Harris, Peter C , Hanna, Christian , Senum, Sarah R , Smith, Byron H. , Torres, Vicente E. , Chebib, Fouad T.

Mayo Clinic

Clinical Kidney Journal | May 24, 2023 | Volume: 16 | Issue: 10 | Pages: 1691-1700

10.1093/ckj/sfad114 | PMID 37779848 Get It

ABSTRACT Background Autosomal dominant polycystic kidney disease (ADPKD) presents with variable disease severity and progression. Advanced imaging biomarkers may provide insights into cystic and non-cystic processes leading to kidney failure in different age groups. Methods This pilot study included 39 ADPKD patients with kidney failure, stratified into three age groups (&lt;46, 46–56, &gt;56 years old). Advanced imaging biomarkers were assessed using an automated instance cyst segmentation tool. The biomarkers were compared with an age- and sex-matched ADPKD cohort in early chronic kidney disease (CKD). Results Ht-total parenchymal volume correlated negatively with age at kidney failure. The median Ht-total parenchymal volume was significantly lower in patients older than 56 years. Cystic burden was significantly higher at time of kidney failure, especially in patients who reached it before age 46 years. The cyst index at kidney failure was comparable across age groups and Mayo Imaging Classes. Advanced imaging biomarkers showed higher correlation with Ht-total kidney volume in early CKD than at kidney failure. Cyst index and parenchymal index were relatively stable over 5 years prior to kidney failure, whereas Ht-total cyst volume and cyst parenchymal surface area increased significantly. Conclusion Age-related differences in advanced imaging biomarkers suggest variable pathophysiological mechanisms in ADPKD patients with kidney failure. Further studies are needed to validate the utility of these biomarkers in predicting disease progression and guiding treatment strategies.
Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Degnim, Amy C. , Siontis, Brittany L. , Ahmed, Safia K. , Hoskin, Tanya L. , Hieken, Tina J. , Jakub, James W. , Baum, Christian L. , Day, Courtney N. , Schrup, Sarah E. , Smith, Lauren , Carter, Jodi M. , Sae-Kho, Tiffany M. , Glazebrook, Katrina N. , Vijayasekaran, Aparna , Okuno, Scott H. , Petersen, Ivy A. , Day, Courtney , Siontis, Brittany L , Hieken, Tina J , Degnim, Amy C , Jakub, James W , Hoskin, Tanya , Carter, Jodi

Mayo Clinic

Clinical Cancer Research | May 24, 2023 | Volume: 29 | Issue: 15 | Pages: 2885-2893

10.1158/1078-0432.ccr-23-0443 | PMID 37223927 Get It

Abstract Purpose: To evaluate the impact of trimodality treatment versus monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment. Experimental Design: With Institutional Review Board approval, we identified patients diagnosed with RAASB and abstracted data on disease presentation, treatment, and oncologic outcomes. Trimodality therapy included (i) taxane induction, (ii) concurrent taxane/radiation, and then (iii) surgical resection with wide margins. Results: A total of 38 patients (median age 69 years) met inclusion criteria. Sixteen received trimodality therapy and 22 monotherapy/dual therapy. Skin involvement and disease extent were similar in both groups. All trimodality patients required reconstructive procedures for wound closure/coverage, compared with 48% of monotherapy/dual therapy patients (P &lt; 0.001). Twelve of 16 (75%) patients receiving trimodality therapy had a pathologic complete response (pCR). With median follow-up of 5.6 years, none had local recurrence, 1 patient (6%) had distant recurrence, and no patients died. Among 22 patients in the monotherapy/dual therapy group, 10 (45%) had local recurrence, 8 (36%) had distant recurrence, and 7 (32%) died of disease. Trimodality therapy demonstrated significantly better 5-year recurrence-free survival [RFS; 93.8% vs. 42.9%; P = 0.004; HR, 7.6 (95% confidence interval, CI: 1.3–44.2)]. Combining all patients with RAASB regardless of treatment, local recurrence was associated with subsequent distant recurrence (HR, 9.0; P = 0.002); distant recurrence developed in 3 of 28 (11%) patients without local recurrence compared with 6 of 10 (60%) with local recurrence. The trimodality group had more surgical complications that required reoperation or prolonged healing. Conclusions: Trimodality therapy for RAASB was more toxic but is promising, with a high rate of pCR, durable local control, and improved RFS.